Previous Article | Next Article ![]()
Journal of Virology, December 2001, p. 11496-11502, Vol. 75, No. 23
Department of Virology, Intervet
International B.V., 5830 AA Boxmeer, The Netherlands
Received 5 July 2001/Accepted 29 August 2001
Rabies virus (RV) is a highly neurotropic virus that migrates from
the portal of entry to the central nervous system (CNS). The
cytoplasmic dynein light chain (LC8), which is involved in a variety of
intracellular motile events, was shown to interact with RV
phosphoprotein (P). In order to determine the functional significance
of this interaction, P residues 143 to 149 or 139 to 149 encompassing a
conserved LC8-interacting motif (K/RXTQT) were deleted
from recombinant viruses SAD-L16 and SAD-D29. These viruses are
identical except for a replacement of the arginine at position 333 (R333) of the RV glycoprotein by an aspartic acid in SAD-D29. SAD-L16
virus is fully pathogenic for mice, whereas SAD-D29 is nonpathogenic
for adult mice but retained pathogenicity for suckling mice. The
deletions introduced into the LC8 binding site abolished the P-LC8
interaction and blocked LC8 incorporation into virions. All the mutants
propagated in cell culture as efficiently as the parent strains. The
pathogenicity of the mutants was then compared with that of the parent
viruses by inoculating suckling mice. SAD-L16 derivatives were as
pathogenic as their parent virus after intramuscular inoculation,
indicating that LC8 is dispensable for the spread of a pathogenic RV
from a peripheral site to the CNS. In contrast, SAD-D29-derived
deletion mutants were attenuated by as much as 30-fold after
intramuscular inoculation but remained as pathogenic as the parent
virus when inoculated directly into the brain. This remarkable
attenuation after intramuscular but not after intracranial inoculation
suggested that abolishing the P-LC8 interaction reduces the efficiency
of peripheral spread of the more attenuated SAD-D29 strain. These
results demonstrate that elimination of the LC8 ligand and simultaneous
substitution of R333 considerably attenuate RV pathogenicity and may be
helpful in designing and developing highly safe live-RV-based vaccines.
Rabies remains one of the most
dreadful neurotropic infectious diseases affecting humans and animals.
Rabies virus (RV) multiplies first at the site of infection and is
transported by retrograde flow through peripheral nerves to the central
nervous system (CNS), where it causes encephalomyelitis. The mechanism
by which RV is transported retrograde from peripheral sites to the
neurons is poorly understood. What has recently been described is that
the cytoplasmic dynein light chain (LC8), which is involved in the retrograde intracellular transport of organelles, interacts with the
phosphoprotein (P) of RV and is incorporated into mature virions (13, 25). The interaction of RV P with LC8 was shown by
coimmunoprecipitation analysis, and mapping studies have demonstrated
that LC8 interacts in the region between residues 138 and 172 of the P
protein. Using biochemical and mutational analysis of selected LC8
binding proteins, Lo et al. (18) identified a consensus
sequence containing a K/RXTQT motif that interacts with LC8.
The involvement of LC8 in various intracellular transport mechanisms
and other cellular functions led to the suggestion that the P-LC8
interaction might be the driving force for the retrograde transport and
pathogenesis of RV. However, the functional significance of this
interaction in the neuroinvasive processes of RV has not yet been elucidated.
RV is a nonsegmented negative-stranded RNA virus of the
Rhabdoviridae family. The viral proteins of RV are
associated either with the core component, called the ribonucleoprotein
(RNP) complex, or with the viral envelope. The RNP complex consists of
the RNA genome encapsidated by the nucleocapsid (N) protein in
combination with polymerase (L) and the P protein. The RNP complex
serves as a template for virus transcription and replication. The P
protein interacts with the N and L proteins (4, 5, 12) and
is believed to work as a noncatalytic cofactor of the viral RNA
polymerase. P protein is multifunctional, binding to other viral
proteins to act as a chaperone to help viral genome replication, and
also interacting with cellular factors, possibly to participate in RV
spread and pathogenesis (13, 25).
The viral envelope component is composed of a transmembrane
glycoprotein (G) and a matrix (M) protein. The M protein is localized on the inner surface of the viral envelope surrounding the RNP and is
involved in the virus assembly and budding process (20). In addition to M protein, the spike G protein also participates in the
virus release process by increasing budding efficiency (22). G protein is responsible for cell attachment and
membrane fusion and is the main protein responsible for the induction
of virus-neutralizing antibodies. Moreover, the G protein is known to
play a role in virulence. In particular, the arginine (R) residue at
position 333 (R333) of the G protein has been shown to be responsible for RV pathogenicity (11, 23, 29). Among several
neutralization-resistant RV mutants generated under selection pressure
with monoclonal antibodies, only mutants that possess an amino acid
differing from R333 of the G protein were found to have reduced
pathogenicity for adult mice (29). This finding confirmed
the presence of a direct correlation between RV pathogenicity and R333
and helped in developing attenuated RV vaccines for oral immunization
of animals (17, 19). Such live rabies vaccine viruses
possessing an amino acid other than R333 in the glycoprotein are
nonpathogenic to immunocompetent adult mice. However, they are still
pathogenic when inoculated into baby mice (33),
demonstrating the existence of residual pathogenicity and the potential
risk to immunocompromised animals and humans.
Despite significant scientific advances in rabies prevention and
control, the disease remains a major threat to public health and
continues to cause numerous human deaths in the tropics. Canine rabies
is still epizootic in most countries of Africa, Asia, and South
America, and infection via dogs is responsible for most human deaths
from the disease. The presence of large numbers of ownerless dogs in
these countries necessitates introduction of new control strategies in
addition to the existing parenteral vaccination programs. Due to the
success in control of wildlife rabies by oral immunization (19,
35), several developing countries are presently volunteering to
make use of oral vaccination of dogs. However, compared to the live
oral vaccine strains used for immunization of wildlife, vaccine strains
for oral immunization of dogs have to be highly safe due to the much
closer relationship between dogs and humans than between wild animals
and humans. Furthermore, there is a growing interest in exploiting the
potential of recombinant RV-based vectors to protect humans and animals from other infectious agents. Recently it has been shown that a
recombinant RV expressing human immunodeficiency virus type 1 (HIV-1)
envelope glycoprotein might serve as a potential vector for an HIV-1
vaccine (28). The success of such RV-based vaccines is,
however, largely dependent on the safety of the RV strain, particularly
in immunocompromised patients.
To define the role of the P-LC8 interaction in virus transport and
virus pathogenesis, it was necessary to construct mutants in which the
LC8 binding domain was modified. The present paper describes the
effects of deletions of either 7 or 11 residues from the LC8 binding
site in the P protein with or without an R333 substitution in the G
protein. Surprisingly, when deletions are introduced into the LC8
binding site of an RV that possesses an amino acid differing from R333,
a dramatic reduction in pathogenicity for 1- to 2-day-old suckling mice
was observed after peripheral inoculation. The profound advantage of
this extensive attenuation of RV in developing live oral rabies
vaccines or RV-based vectors with eliminated or diminished risks
associated with retrograde neuronal spread is discussed.
Cells and viruses.
A recombinant RV, SAD-L16, possessing the
authentic sequence of the attenuated SAD-B19 (6) vaccine
strain (a derivative of the Street Alabama Dufferin strain [SAD]),
was generated from a full-length cDNA clone (27). BSR-T7/5
cells expressing phage T7 RNA polymerase in a stable manner
(3) were used to recover infectious RV from cDNA.
Construction of cDNA clones.
In order to introduce deletions
into the LC8 binding site of the P protein, a 2.2-kb BstBI
fragment comprising nucleotides 1497 to 3738 of the SAD B19 sequence
was first cloned into the pSK vector. Site-directed mutagenesis was
carried out using the QuikChange site-directed mutagenesis kit
according to the manufacturer's (Stratagene) instructions. Primer
pairs 142 (5'-GGAAAGTCTTCAGAGGGCCGAGAGCTCAAG-3') and 143 (5'-CTTGAGCTCTCGGCCCTCTGAAGACTTTCC-3') were used to delete nucleotides in positions 1940 to 1960, corresponding to amino acids 143 to 149 of the RV P protein. A larger deletion encompassing nucleotides
1928 to 1960, which corresponds to amino acids 139 to 149 of RV P
protein, was also introduced using oligonucleotides 144 (5'-CCCAACCCTCCAGGAGGCCGAGAGCTCAAG-3') and 145 (5'-CTTGAGCTCTCGGCCTCCTGGAGGGTTGGG-3'). The accuracy of the
introduced deletions was confirmed by sequencing the modified region.
Clones containing the desired deletions (7 or 11 amino acids) were
digested with NcoI and SnaBI, and the respective
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11496-11502.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Extensive Attenuation of Rabies Virus by
Simultaneously Modifying the Dynein Light Chain Binding Site in the P
Protein and Replacing Arg333 in the G Protein
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
0.8-kb fragments were introduced into the full-length clone SAD-L16
after removing the corresponding fragment. The resulting plasmids
encoding deletions of 7 or 11 residues in the LC8 binding site of P
protein were named L-
P7 and L-
P11, respectively (Fig. 1A).

View larger version (20K):
[in a new window]
FIG. 1.
Schematic representation of the RV gene order in the
negative-strand genomic RNA. (A) Recombinant RV SAD-L16, possessing the
authentic sequence of SAD-B19 (6), which has an arginine
(R333) at position 333 of the G protein. (B) Recombinant RV SAD-D29,
possessing an aspartic acid (D333) at position 333 of the G protein.
Amino acid sequences around the LC8 dynein light chain-binding site of
the P protein (positions 138 to 150) are presented. The P protein
sequence KSTQT (positions 144 to 148) is identical to the
K/RXTQT motif found in a variety of proteins interacting
with LC8. The
P7 and
P11 mutants constructed in the backbone of
SAD-L16 and SAD-D29 contain the indicated deletions of 7 or 11 amino
acids at the LC8 binding site of the respective P proteins.
0.8-kb DNA fragments possessing deletions in the LC8 binding site
were used to replace the corresponding fragment of SAD-D29. The
resulting full-length clones having D333 instead of R333 in the G
protein and simultaneously a deletion of 7 or 11 amino acids at the LC8
binding site of the P protein were named D-
P7 and D-
P11,
respectively (Fig. 1B).
Recovery of recombinant viruses. Transfection experiments were carried out as described previously (27). Approximately 1.5 × 106 BSR-T7/5 cells were transfected with a plasmid mixture containing 5 µg of pT7T-N, 2.5 µg of pT7T-P, 2.5 µg of pT7T-L, and 10 µg of one of the full-length plasmids using the Stratagene mammalian transfection kit (CaPO4 protocol). Supernatants from transfected cells were passaged, and infection of cells was monitored by direct immunofluorescence with an anti-RV nucleoprotein conjugate (Centocor). The recombinant viruses were further passaged two to three times, and the resulting virus stocks were titrated by endpoint dilutions.
Replication of recombinant viruses in vitro. For one-step growth curve analysis, 106 BSR-T7/5 cells were grown in 3.2-cm-diameter dishes overnight and infected in duplicate at a multiplicity of infection (MOI) of 10 with the various recombinant viruses. After 2 h of incubation at 37°C, the inoculum was removed, and the cells were rinsed three times with phosphate-buffered saline (PBS). Cells were supplied with 2.5 ml of fresh medium and incubated further at 37°C. At 4, 18, 24, and 48 h after infection, 100 µl of culture supernatants was removed and counted in duplicate on BSR-T7/5 cells. A multicycle growth analysis was done as above except that the infection of BSR-T7/5 cells was done at an MOI of 0.01.
RT-PCR and sequence analysis. To determine whether the recombinant viruses maintained the introduced deletions, total RNA was isolated from BSR-T7/5 cells infected with passage level 4 of the respective stock viruses. Reverse transcription (RT)-PCR was performed on 1 µg of total RNA isolated from infected cells. The PCR products were analyzed on 1% agarose gels and used directly for sequencing.
Protein composition of mutant viruses and
coimmunoprecipitation.
To analyze the protein composition of
recombinant viruses,
107 BSR-T7/5 cells were
infected at an MOI of 0.02 and incubated for 2 days. Virions in the
supernatant were then purified and concentrated by centrifugation
through a 20% sucrose cushion in a Beckman SW28 rotor at 25,000 rpm
for 90 min. Pellets were resuspended and mixed with protein sample
buffer to disrupt the virions. Viral proteins from purified virions
were then resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes
(Millipore). After incubation with a blocking solution, membranes were
incubated with rabbit serum raised against RV ribonucleoprotein S50
(22) or a rabbit polyclonal anti-LC8 antibody, R4058
(15). Membranes were then incubated with
peroxidase-conjugated goat anti-rabbit immunoglobulin G. Proteins were
visualized after incubation with peroxidase substrate (Vector).
Pulldown experiments were performed by immunoprecipitating samples of
cytoplasmic extracts of infected BSR-T7/5 cells with the anti-RV RNP
serum S50. Coimmunoprecipitation of LC8 was then analyzed by Western
blotting after incubating blots with the anti-LC8 antibody.
Pathogenicity of recombinant viruses in mice. Groups of six 1- to 2-day-old or 1-week-old suckling BALB/c mice were inoculated by the intramuscular (i.m.) route in the hind thigh region or by the intracranial (i.c.) route with a volume of 0.03 ml of virus suspensions at various concentrations. Mice were observed for rabies symptoms for 21 days. A 20% brain suspension was prepared from dead mice, and the presence of RV in the brain was confirmed by virus isolation in cell culture. At the end of the 21-day observation period, brain samples from surviving mice were also processed for virus isolation. The lethal dose that kills 50% of the animals (LD50) was calculated using the method of Reed and Muench (26).
| |
RESULTS |
|---|
|
|
|---|
Generation of mutant RVs from cDNA. The finding of an interaction between the P protein of RV and the LC8 dynein light chain led to the suggestion that the retrograde transport of RV from the portal of entry might be mediated by LC8. RV P residues 138 to 172 have been mapped as domains responsible for binding to the LC8 dynein light chain (25). Moreover, comparison of P protein sequences of various RV strains reveals the presence of a conserved KSTQT sequence (residues 144 to 148), which is identical to the consensus LC8 binding motif (K/RXTQT) of various LC8 binding proteins (18).
To obtain insight into the functional significance of the LC8-P interaction, RV mutants possessing 7 or 11 amino acid deletions in the binding site encompassing residues 143 to 149 (
7 mutants) or
residues 139 to 149 (
11 mutants) were constructed (Fig. 1). The
deletions were first introduced into the backbone of recombinant RV
SAD-L16, which possesses the authentic sequence of the attenuated RV
strain SAD-B19 (6, 27).
For the purpose of developing genetically stable attenuated live oral
rabies vaccine candidates and RV-based vaccine vectors, RV mutants
possessing replacements of R333 were generated and characterized (not
shown). Among the various R333 mutants, a mutant (SAD-D29) possessing
an aspartic acid (D333) instead of R333 was chosen for further
modification. The 7 or 11 amino acid deletions in the LC8 binding
domain were then introduced into the backbone of SAD-D29 (Fig. 1).
Full-length cDNA clones representing all the mutants were transfected
as described in Materials and Methods. For all the mutants, the
presence of infectious virus was detected after one passage of the
transfection supernatants into fresh BSR-T7/5 cells. Stock viruses for
further analysis were prepared after two to three passages in BSR-T7/5
cells. The identity of the recombinant viruses SAD-D29, D-
P7,
D-
P11, L-
P7, and L-
P11 (Fig. 1) was verified by RT-PCR and by
sequencing of PCR products. For all mutants, the sequences obtained
corresponded exactly to the alterations introduced into the cDNA clones.
Propagation of recombinant viruses in cell culture.
First, the
titers of the stock viruses were determined by endpoint dilutions. To
examine the efficiency of virus propagation at different time points, a
multicycle growth curve analysis was performed by infecting BSR-T7/5
cells at an MOI of 0.01. In the titers determined during the first
18 h, SAD-L16 gave slightly higher titers than the rest of the
recombinants, but this pattern disappeared at 24 h postinfection.
At 48 h of infection, the titers of all the recombinants were very
similar (Fig. 2A). To allow synchronous
infection of all cells, BSR-T7/5 cells were also infected at an MOI of
10 and aliquots of cell culture supernatants were collected for titer
determination at the indicated time points (Fig. 2B). At 18 h
postinfection, the virus with the highest titer was the mutant
L-
P11, and at 24 h postinfection all viruses yielded very
similar titers. No specific pattern of growth impairment was seen for
any of the mutants, indicating that as many as 11 amino acids at the
LC8 binding site in the P protein are dispensable for RV replication in
cell culture.
|
Protein composition of mutants.
To determine the expression
level of mutant P proteins and to elucidate whether LC8 was
incorporated into virions, proteins from purified viruses were analyzed
by Western immunoblotting. The blots were incubated with an anti-RV RNP
rabbit serum (S50) or an anti-LC8 polyclonal antibody (R4058). The
amounts of P protein and the ratios between P and N proteins of the
mutant viruses were indistinguishable from those of the parent viruses,
indicating that the deletion of 7 or 11 amino acids from the LC8
binding site had no influence on expression of mutated P proteins. In contrast to the parent viruses, no protein corresponding to LC8 could
be detected in mutant viruses with a deletion at the LC8 binding site
(Fig. 3). This result demonstrates that
the introduced deletions were sufficient to entirely block the
incorporation of LC8 into virions.
|
Pathogenicity of recombinant viruses in mice.
The parent
SAD-L16 virus causes 100% mortality after i.c. inoculation into adult
mice with a dose as low as 30 focus-forming units (FFU)/mouse. In
contrast, SAD-D29 was completely nonpathogenic for adult mice even at a
dose higher than 106 FFU/mouse. However, it
retained full pathogenicity for 1- to 2-day-old suckling mice. Due to
the suggestion that LC8 might be involved in the axonal transport of
RV, it was logical to first use a peripheral route of
inoculation to compare LC8 binding site mutants with their parents. In
the first experiment, 1-week-old suckling mice were inoculated by i.m.
injection at doses of 102 or
105 FFU/mouse. Unexpectedly, SAD-L16, L-
P7,
and L-
P11 were equally pathogenic for 1-week-old suckling mice,
indicating that LC8 is not required for the spread of SAD-L16 from a
peripheral site of inoculation in this model (Fig.
4). In contrast, SAD-D29, D-
P7, and
D-
P11 were all nonpathogenic at the doses administered (Fig. 4).
|
P7, and L-
P11 died of rabies within 10 days of
inoculation. This again demonstrated that deletion of 7 or 11 residues
from the LC8 binding site of the P protein does not affect the
peripheral spread of SAD-L16 in suckling mice. However, when the LC8
binding site deletion mutations are combined with the R333 substitution mutation, a substantial degree of attenuation of SAD-D29 was achieved. Within 10 days postinoculation, all mice inoculated with both doses of
the parent SAD-D29 had died of rabies. In contrast, lower mortality
rates of 83 and 50% occurred in the groups of mice that received
105 FFU/mouse of D-
P7 or D-
P11,
respectively (Fig. 5). Fifteen days after infection, the mortality
reached 100 and 83% (five of six), respectively, and remained the same
until the end of the 21-day observation period (Fig. 5).
|
P7 or D-
P11 at a dose of 102
FFU/mouse until 11 days postchallenge. Total mortality during the
21-day observation period was less than 17% (one of six) for the
D-
P7-inoculated group, whereas no mice died in the
D-
P11-inoculated group. These results demonstrate that the
combination of LC8 binding site mutation and the amino acid change at
R333 of the G protein considerably attenuate RV virulence for 1- to
2-day-old suckling mice.
Next, the degree of attenuation of the recombinant D-
P11 was
analyzed by administering graded doses into 1- to 2-day-old suckling
mice by the i.m. or i.c. route. In an earlier experiment, one of six
mice survived after infection with D-
P11 at a dose of
105 FFU/mouse (83% mortality, Fig. 5). In this
independent experiment, doses of 105 (not shown)
and 104 FFU/mouse killed all inoculated animals
(Fig. 6). However, as in the previous
experiment, D-
P11 administered at a dose of
102 FFU/mouse by i.m. injection was completely
nonpathogenic for 1- to 2-day-old suckling mice. As shown in Fig. 6,
the dose of D-
P11 that was required to kill 50%
(LD50 per 30 µl) of the i.m.-inoculated 2-day-old suckling mice was 556 FFU, whereas the
LD50 of the parent SAD-D29 virus was only 18 FFU.
This demonstrates that D-
P11 is attenuated by as much as 30-fold
when administered by the i.m. route. Interestingly, very similar
LD50s of 10 and 14 FFU were obtained for SAD-D29
and D-
P11, respectively, when the strains were administered i.c.
(Fig. 6). This remarkable attenuation after i.m. but not after i.c.
administration shows that D-
P11 spreads inefficiently from a
peripheral site of infection to the CNS compared to the parent virus.
|
| |
DISCUSSION |
|---|
|
|
|---|
Neurotropism is one of the most striking biological characteristics of RV infection. RV enters the body in the bite or when virus-laden saliva from a rabid animal enters an open wound. After viral replication at the portal of entry, RV is believed to enter nerve endings and spread centripetally along peripheral nerves and eventually gain access to the CNS. However, the events of RV dissemination from the portal of entry to the CNS are among the most obscure events of the infection. The strict neurotropic characteristics of RV suggest the involvement of neuronal receptors for entry of the virus into nerves (32, 34). Nevertheless, the recent description of an interaction between LC8 and RV P is relevant to speculation about the involvement of cellular factors besides neuronal receptors (13, 25). To determine the functional significance of the LC8-P interaction in RV dissemination and pathogenesis, RV P protein mutants possessing deletions in the LC8 binding site were generated and characterized. A substantial degree of attenuation of RV for 1- to 2-day-old suckling mice was achieved by combining the LC8 binding site mutation with that of R333 substitution.
LC8 has been implicated in a wide variety of cellular functions, ranging from intracellular organelle transport to regulation of cellular functions. The finding that LC8 interacts with the P protein of RV led to suggestions that LC8 may be involved in the axonal transport and pathogenesis of RV (13, 25). In order to define the role of this interaction in RV neurotropism, it was necessary to construct mutants in which the LC8 binding domain was modified by deletion or mutagenesis. The LC8 binding domain was mapped to the central part of P, encompassing residues 138 to 172 (25). Based on biochemical and mutational analysis of selected LC8 binding proteins, Lo et al. (18) recently showed that LC8 binds to its targets via a conserved K/RXTQT motif. In addition, sequence alignment analysis of P proteins from various RV strains demonstrated the existence of a conserved KSTQT sequence (residues 144 to 148), suggesting that LC8 binds to P protein via this motif.
RV mutants possessing 7 or 11 amino acid deletions in the binding site propagated in cell culture with comparable efficiency and to similar titers as the parent viruses, demonstrating that the introduced deletions have no influence on the efficiency of virus replication in cell culture (Fig. 2). As demonstrated by immunoblotting analyses of purified virions, the amount of P protein and the P-to-N ratio in the mutants were indistinguishable from those of the parent viruses. Moreover, incubation of blots with LC8 antibody clearly demonstrated the absence of LC8 in purified virions as well as in cell lysates subjected to coimmunoprecipitation experiments. Titration of aliquots of supernatants subjected to immunoblotting revealed comparable titers, ranging from 8.0 log10 FFU/ml for SAD-L16 to 8.15 log10 FFU/ml for SAD-D29. Although the levels of the more abundant P and N proteins were indistinguishable, this slight titer difference might have contributed to the different amounts of the less-abundant LC8 observed in SAD-L16 and SAD-D29 viruses (Fig. 3). Taken together, these results demonstrate that LC8 incorporation into RV virions is mediated by a specific interaction with P protein rather than a passive entrapment into the virion envelope. Moreover, deletion of residues 143 to 149 from the LC8 binding site was sufficient to completely abolish the P-LC8 interaction and to block incorporation of LC8 into mature virions. In agreement with this finding, Lo et al. (18) demonstrated that a single change in one of the four consensus amino acid residues in the K/RXTQT motif can weaken or entirely abolish the binding of a peptide to LC8. The mutational analysis also suggested that the TQT tripeptide plays a more dominant role in the interaction between LC8 and its target proteins.
Pathogenicity of RV is usually measured by inoculating mice via different routes. The virus strain, the route of inoculation, and the age of the mice are important factors in determining RV virulence. In order to determine whether the mutations introduced into the LC8 binding site block the spread of the virus from peripheral sites to the CNS, 1-week-old suckling mice were inoculated by i.m. administration. As shown in Fig. 4, SAD-L16 and mutant derivatives were equally pathogenic, whereas SAD-D29 and its derivatives were all nonpathogenic. This result raises obvious questions as to why the L16-derived mutants are as pathogenic as their parent virus in spite of the absence of the P-LC8 interaction. In experiments carried out in 1- to 2-day-old mice, the pathogenicity of SAD-L16 and its derivatives was again indistinguishable. In both models, the P-LC8 interaction seems to be not at all necessary for spread of the less attenuated SAD-L16 from a peripheral site of inoculation.
In an attempt to see differences between the attenuated SAD-D29 and its
derivatives, similar experiments were carried out in more sensitive 1- to 2-day-old mice. Surprisingly, the elimination of the LC8 ligand
through deletion of critical residues from the binding site and the
simultaneous R333 substitution considerably reduced the pathogenicity
of RV strains D-
P7 and D-
P11 after peripheral inoculation (Fig.
5). Very marginal differences between the mortality levels of D-
P7
and D-
P11 were observed (one more mouse died in the group of
mice inoculated with D-
P7 than in the group inoculated with
D-
P11; see Results section). However, due to deletion of four more
amino acids in the P protein in D-
P11 than in D-
P7, minor
impairment of D-
P11 in in vivo replication cannot be excluded.
Antigenic site III of RV G protein, particularly R333, has been implicated as playing an important role in RV neuroinvasive processes (11, 23, 29). Although R333 mutants were able to penetrate neuron cells as efficiently as the wild-type parent strains, their propagation was restricted after the second and third cycles, demonstrating a defect in trans-neuronal transfer (9). Moreover, the presence of R333 and a lysine at position 330 of the G protein has been shown to be important for RV to be able to bind to neuronal receptors and propagate in motoneurons (10, 34). It appears that R333 plays a dominant role in RV neuroinvasion, and the role of LC8 comes to light when the function of R333 is hampered.
To determine the degree of attenuation of the deletion mutants, graded
doses of D-
P11 and SAD-D29 were administered to 1-to 2-day-old
suckling mice i.m. or i.c. Compared to the parent virus, D-
P11 was
attenuated by as much as 30-fold when administered by the i.m. route.
Interestingly, the LD50 of both viruses was nearly identical by the i.c. route, indicating that D-
P11 spreads inefficiently from a peripheral site of inoculation to the CNS. The
involvement of cytoplasmic dynein and the microtubular network in the
retrograde transport of some viruses, including herpes simplex virus
type 1, adenovirus, and pseudorabies virus, has been described in the
past (14, 30, 31, 36). Furthermore, LC8 was shown to be
essential for retrograde intraflagellar transport in
Chlamydomonas (16, 24). These findings
indicate that various organisms may utilize cytoplasmic dynein as a
motor in reaching their preferred site. In the case of RV, however,
abolishing the P-LC8 interaction affected only the efficiency of
peripheral spread of the more attenuated strain lacking R333, but even
for this recombinant (D-
P11), LC8 was dispensable at higher dose
levels (Fig. 6). Although a substantial degree of attenuation was
achieved by combining the R333 and LC8 binding site mutations, the
contribution of LC8 to the peripheral spread of a fully virulent RV
appears to be limited. Therefore, cellular factors other than LC8 or an entirely different mechanism should be involved in the retrograde axonal transport of RV. Future work should provide direct evidences for
the contribution of LC8 to RV axonal transport and elucidate the
neoroinvasive processes during RV infection.
The findings that RV infection in mice could take place in the oral mucosa (8) and that foxes could be immunized by oral administration of live attenuated RV (1, 2) led to the present-day wildlife rabies control programs of oral vaccinations (reviewed in reference 35). Two of the serious problems presented by the oral vaccine viruses were residual pathogenicity for target and nontarget species as well as the possibility of reversion to virulence. Significant advances in increasing the safety of oral rabies vaccine strains was made by selecting monoclonal antibody-resistant mutants with mutations at R333 (11, 29). Derivatives of SAD virus possessing amino acids differing from R333 have been developed for oral immunization of foxes and other animals (19).
Unlike other attenuated mutants such as SAD-Bern and SAD-B19
(35), R333 mutants are nonpathogenic for adult mice after
i.c. inoculation. However, these strains remained pathogenic for baby mice, suggesting the potential danger of such live vaccines for immunocompromised humans who may come in contact with the virus. In
this work, by applying the reverse genetics technology, an extensive
attenuation of R333 mutants was achieved by deleting critical residues
from the LC8 binding site in the P protein. The introduction of
the combined mutations into the P and G proteins did not affect in
vitro replication. This makes recombinant RV mutants D-
P7 and
D-
P11 potential candidates for oral immunization of animals.
Highly safe live rabies vaccine viruses can not only be used to
immunize against rabies, but potentially can also serve as vaccine
vectors to protect humans and animals from other infectious agents. In
addition to the five viral proteins, RV has been shown to express
foreign genes in a stable manner for more than 25 serial passages
(21). The potential of RV-based vectors as vaccines against other viral diseases such as AIDS was also demonstrated recently (28). The introduction of the described combined
G and P protein mutations into RV vectors will undoubtedly diminish the
risk associated with residual pathogenicity of RV and facilitate the
design of safe RV-based vectors. The substantially attenuated D-
P7 and D-
P11 viruses are not only attractive candidates for live RV based vaccines but also provide some insight into the ill-defined events of RV dissemination through peripheral nerves to the CNS.
| |
ACKNOWLEDGMENTS |
|---|
I am grateful to L. T. C. de Vaan, M. Braber, and N. de Haas for perfect technical assistance, E. Schuurmans for digitizing Fig. 3, and S. King for kindly providing the anti-LC8 antibody. I thank colleagues from the animal service department of Intervet for their assistance and A. Gray, P. van der Marel, and I. Tarpey for valuable suggestions on the manuscript.
| |
FOOTNOTES |
|---|
* Mailing address: Department of Virology, Intervet International B.V., P.O. Box 31, 5830 AA Boxmeer, The Netherlands. Phone: 31 485 587 351. Fax: 31 485 587 339. E-mail: teshome.mebatsion{at}intervet.com.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Baer, G. M.,
M. K. Abelsth, and J. G. Debbie.
1971.
Oral vaccination of foxes against rabies.
Am. J. Epidemiol.
93:487-490 |
| 2. | Black, J. G., and K. F. Lawson. 1970. Sylvatic rabies studies in the silver fox (Vulpes vulpes): susceptibility and immune response. Can. J. Comp. Med. 34:309-311[Medline]. |
| 3. |
Buchholz, U. J.,
S. Finke, and K.-K. Conzelmann.
1999.
Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter.
J. Virol.
73:251-259 |
| 4. |
Chenik, M.,
K. Chebli,
Y. Gaudin, and D. Blondel.
1994.
In vivo interaction of rabies virus phosphoprotein (P) and nucleoprotein (N), existence of two N binding sites on P protein.
J. Gen. Virol.
75:2889-2896 |
| 5. |
Chenik, M.,
M. Schnell,
K.-K. Conzelmann, and D. Blondel.
1998.
Mapping the interacting domains between the rabies virus polymerase and phosphoprotein.
J. Virol.
72:1925-1930 |
| 6. | Conzelmann, K.-K., J. H. Cox, L. G. Schneider, and H.-J. Thiel. 1990. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175:485-499[CrossRef][Medline]. |
| 7. |
Conzelmann, K.-K., and M. Schnell.
1994.
Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins.
J. Virol.
68:713-719 |
| 8. |
Correa-Giron, E. P.,
R. Allen, and S. E. Sulkin.
1970.
The infectivity and pathogenesis of rabies virus administered orally.
Am. J. Epidemiol.
91:203-215 |
| 9. |
Coulon, P.,
C. Derbin,
P. Kucera,
F. Lafay,
C. Prehaud, and A. Flamand.
1989.
Invasion of the peripheral nervous systems of adult mice by the CVS strain of rabies virus and its avirulent derivative AvO1.
J. Virol.
63:3550-3554 |
| 10. |
Coulon, P.,
J.-P. Ternaux,
A. Flamand, and C. Tuffereau.
1998.
An avirulent mutant of rabies virus is unable to infect motor neurons in vivo and in vitro.
J. Virol.
72:273-278 |
| 11. |
Dietzschold, B.,
W. H. Wunner,
T. J. Wiktor,
A. D. Lopes,
M. Lafon,
C. L. Smith, and H. Koprowski.
1983.
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.
Proc. Natl. Acad. Sci. USA
80:70-74 |
| 12. | Fu, Z. F., Y. Zheng, W. H. Wunner, H. Koprowski, and B. Dietzschold. 1994. Both the N- and the C-terminal domains of the nominal phosphoprotein of rabies virus are involved in binding to the nucleoprotein. Virology 200:590-597[CrossRef][Medline]. |
| 13. |
Jacob, Y.,
H. Badrane,
P.-E. Ceccaldi, and N. Tordo.
2000.
Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein.
J. Virol.
74:10217-10222 |
| 14. |
Kaelin, K.,
S. Dezelee,
M. J. Masse,
F. Bras, and A. Flamand.
2000.
The UL25 protein of pseudorabies virus associates with capsids and localizes to the nucleus and to microtubules.
J. Virol.
74:474-482 |
| 15. |
King, S. M., and R. S. Patel-King.
1995.
The Mr = 8,000 and 11,000 outer arm dynein light chains from Chlamydomonas flagella have cytoplasmic homologues.
J. Biol. Chem.
270:11445-11452 |
| 16. |
King, S. M.,
E. Barbarese,
J. F. Dillmann III,
R. S. Patel-King,
J. H. Carson, and K. K. Pfister.
1996.
Brain cytoplasmic and flagellar outer arm dyneins share a highly conserved Mr 8000 light chain.
J. Biol. Chem.
271:19358-19366 |
| 17. | Lafay, F., J. Benejean, C. Tuffereau, A. Flamand, and P. Coulon. 1994. Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine 12:317-320[CrossRef][Medline]. |
| 18. |
Lo, K. W.-H.,
S. Naisbitt,
J.-S. Fan,
M. Sheng, and M. Zhang.
2001.
The 8-kDa dynein light chain binds to its targets via a conserved (K/RXTQT) motif.
J. Biol. Chem.
276:14059-14066 |
| 19. | Masson, E., F. Cliquet, M. Aubert, J. Barrat, A. Aubert, M. Artois, and C. L. Schumacher. 1996. Safety study of the SAG2 rabies virus mutant in several non-target species with a view to its future use for the immunization of foxes in Europe. Vaccine 14:1506-1510[CrossRef][Medline]. |
| 20. |
Mebatsion, T.,
F. Weiland, and K.-K. Conzelmann.
1999.
Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein.
J. Virol.
73:242-250 |
| 21. |
Mebatsion, T.,
M. J. Schnell,
J. H. Cox,
S. Finke, and K.-K. Conzelmann.
1996.
Highly stable expression of a foreign gene from rabies virus vectors.
Proc. Natl. Acad. Sci. USA
93:7310-7314 |
| 22. | Mebatsion, T., K. Matthias, and K.-K. Conzelmann. 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 84:941-951[CrossRef][Medline]. |
| 23. | Morimoto, K., J. P. McGettingan, H. D. Foley, D. C. Hooper, B. Dietzschold, and M. J. Schnell. 2001. Genetic engineering of live rabies vaccines. Vaccine 19:3543-3551[CrossRef][Medline]. |
| 24. |
Pazour, G. J.,
C. G. Wilkerson, and G. B. Witman.
1998.
A dynein light chain is essential for the retrograde particle movement of intraflagellar transport (IFT).
J. Cell Biol.
141:979-992 |
| 25. |
Raux, H.,
A. Flamand, and D. Blondel.
2000.
Interaction of the rabies virus P protein with the LC8 dynein light chain.
J. Virol.
74:10212-10216 |
| 26. | Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent end points. Am. J. Hyg. 27:493-497. |
| 27. | Schnell, M. J., T. Mebatsion, and K.-K. Conzelmann. 1994. Infectious rabies viruses from cloned cDNA. EMBO J. 13:4195-4203[Medline]. |
| 28. |
Schnell, M. J.,
H. D. Foley,
C. A. Siler,
J. P. McGettigan,
B. Dietzschold, and R. J. Pomerantz.
2000.
Recombinant rabies virus as potential live-viral vaccines for HIV-1.
Proc. Natl. Acad. Sci. USA
97:3544-3549 |
| 29. |
Seif, I.,
P. Coulon,
P. E. Rollin, and A. Flamand.
1985.
Rabies virulence: Effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.
J. Virol.
53:926-934 |
| 30. |
Sodeik, B.,
M. W. Ebersold, and A. Helenius.
1997.
Microtubule-mediated transport of incoming herpes simplex 1 virus capsid to the nucleus.
J. Cell Biol.
136:1007-1021 |
| 31. |
Suomalainen, M.,
M. Y. Nakano,
S. Keller,
K. Boucke,
R. P. Stidwill, and U. F. Greber.
1999.
Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus.
J. Cell Biol.
144:657-672 |
| 32. |
Thoulouze, M. I.,
M. Lafage,
M. Schachner,
U. Hartmann,
H. Cremer, and M. Lafon.
1998.
The neural cell adhesion molecule is a receptor for rabies virus.
J. Virol.
72:7181-7190 |
| 33. | Tuffereau, C., H. Leblois, J. Benejean, P. Coulon, F. Lafay, and A. Flamand. 1989. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in mice. Virology 172:206-212[CrossRef][Medline]. |
| 34. |
Tuffereau, C.,
J. Benejean,
A.-M. Roque Alfonso,
A. Flamand, and M. C. Fishman.
1998.
Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surface of lepidoptera cells.
J. Virol.
72:1085-1091 |
| 35. | Vos, A., T. Müller, P. Schuster, H. Schlüter, and A. Neubert. 2000. Oral vaccination of foxes against rabies with SAD B19 in Europe, 1983-1998: a review. Vet. Bull. 70:1-6. |
| 36. |
Ye, G. J.,
K. T. Vaughan, and B. Roizman.
2000.
The herpes simplex virus 1 U(L)34 protein interacts with a cytoplasmic dynein intermediate chain and targets nuclear membrane.
J. Virol.
74:1355-1363 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»